Somai Pharmaceuticals Partners with Airo Brands for Global Expansion
Portuguese-based pharmaceutical company Somai Pharmaceuticals recently announced its entry into the Australian market. The company plans to collaborate with American e-cigarette company Airo Brands to manufacture and distribute a range of e-cigarette and e-liquid products.
Pharmaceutical company Somei operates a 3800-square-meter factory near Lisbon, where it exclusively produces the Airo e-cigarette battery technology and its AiroPod e-liquid formula. The first batch of products is expected to be launched in the second quarter of this year under the Special Access Scheme, and sales are also anticipated in Germany, Poland, and Switzerland.
Airo Company was established in 2017 and its innovative tobacco products have been licensed for sale in more than 1700 medical and adult-use marijuana dispensaries across 23 states in the United States and Puerto Rico.
For Solmax, a company engaged in the extraction, research, development, formulation, and distribution of pharmaceutical cannabis products complying with EU GMP regulations, the Airo product holds the potential to become their first batch of products distributed in Australia.
Somai Founder and CEO, Michael Sassano, expressed that this collaboration will position Airo "ahead of other companies in global expansion." He stated, "Our Airo products will meet the European Union GMP quality standards worldwide, and as the global market expands, we will propel the entire Airo product range into an even brighter future." Both Europe and other continents are progressing, and we are honored to bring the finest vaporizers to the global market.
Richard Yost, CEO of Airo, has referred to this collaboration as a "milestone" and emphasized the significance of finding a partner that shares their commitment to quality and consumer focus. According to Yost, they have identified these qualities in Soma.
We were not only impressed by their advanced factory in Portugal, but also by the quality of their team.
Disclaimer:
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.
